A B-D-Glucan Driven Antifungal Stewardship Approach to Manage Empirical Therapy in Patients at Very High Risk for Invasive Candidiasis: a ... View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2017-2020

ABSTRACT

This is a multicenter, prospective, open-label, randomized trial. Patients with severe abdominal condition developing severe sepsis or septic shock and receiving broad spectrum antibiotic and antifungal treatment will be randomized (1:1) to:discontinue antifungal treatment based on negative (<80 pg/ml) result of 1,3 beta-d-glucan performed on day 0,3,6 and 10continue antifungal treatment according with attending physician's decision. Detailed Description Primary objective:Our objective is to establish whether a strategy based on beta-d-glucan (BG) assessment could achieve reduced antifungal consumption in patients with severe abdominal condition developing severe sepsis and septic shock without any impact on the outcome Secondary objectives i) Assess the accuracy of BG in the diagnosis of invasive candidiasis (IC) in in critically ill patients with a severe abdominal condition who develop severe sepsis or septic shock.ii) Describe the changes over the time of BG value according with colonization status, infection or none the aforementioned events.Material and Methods Study design: a multicenter, open label, randomized trial Population: all the patients with a severe abdominal condition who develop a severe sepsis or septic shock.Inclusion Criteria:adult (≥ 18 year) patients;signed informed consent before surgical procedure;severe sepsis or septic shock;at least one of the following conditions: i) post-operative peritonitis, ii) recurrent gastrointestinal perforation, iii) post-operative hepatobiliary and/or pancreatic disorders including necrotizing pancreatitis, iv) post-operative intra-abdominal abscess, and v) anastomotic leak.Exclusion criteria a. diagnosis of candidiasis before the enrollment b. exposure in the past 30 days to any antifungal treatment or diagnosis of invasive fungal infection; c. pregnancy or lactation; d. history of allergy to any of the antifungal drugs; e. major immunosuppression conditions including: i. neutropenia (<0.5 × 109 neutrophils/L [<500 neutrophils/mm3] for >10 days), ii. receipt of an allogeneic stem cell transplant or solid organ transplantation, iii. inherited severe immunodeficiency (such as chronic granulomatous disease or severe combined immunodeficiency), iv. HIV infection with lymphocyte T CD4+ cell count < 200/mmc. f. patients with poor prognosis or unable to sign informed consent.Procedures Pre-randomization proceduresAt the time of patient enrollment (within 24 h from onset of severe sepsis/septic shock), a standardized diagnostic work-up must be performed including at least:i) two sets of blood cultures; ii) 5 surveillance cultures (rectal swab, urine culture, pharyngeal swab, axillary swab, groin swab).iii) in case of re-intervention or percutaneous drainage: Gram stain and culture of intra-abdominal samples; iv) serum BG determination. Antibiotic and antifungal empirical therapy should be started immediately after collection of microbiological samples according with a predefined standard of care (see appendix 1). Once completed this procedures patients will proceed to randomization.Randomization Patient eligible for the study after the beginning of antifungal therapy will be randomized 1:1 to receive (Group A) a BG driven de-escalation strategy or (Group B) a course of antifungal treatment based on the care provider's decision.In both groups, if cultures yield invasive candidiasis (see below) the patient will be managed in according with guidelines and excluded from the per-protocol analysis.In both groups, BG determination will be repeated at day +3, +6 and +10 after starting antifungal therapy.Randomization will be carried out providing closed envelopes to the participating centers immediately before the study onset. More... »

URL

https://clinicaltrials.gov/show/NCT03090334

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "This is a multicenter, prospective, open-label, randomized trial. Patients with severe abdominal condition developing severe sepsis or septic shock and receiving broad spectrum antibiotic and antifungal treatment will be randomized (1:1) to:discontinue antifungal treatment based on negative (<80 pg/ml) result of 1,3 beta-d-glucan performed on day 0,3,6 and 10continue antifungal treatment according with attending physician's decision.\n\nDetailed Description\nPrimary objective:Our objective is to establish whether a strategy based on beta-d-glucan (BG) assessment could achieve reduced antifungal consumption in patients with severe abdominal condition developing severe sepsis and septic shock without any impact on the outcome Secondary objectives i) Assess the accuracy of BG in the diagnosis of invasive candidiasis (IC) in in critically ill patients with a severe abdominal condition who develop severe sepsis or septic shock.ii) Describe the changes over the time of BG value according with colonization status, infection or none the aforementioned events.Material and Methods Study design: a multicenter, open label, randomized trial Population: all the patients with a severe abdominal condition who develop a severe sepsis or septic shock.Inclusion Criteria:adult (\u2265 18 year) patients;signed informed consent before surgical procedure;severe sepsis or septic shock;at least one of the following conditions: i) post-operative peritonitis, ii) recurrent gastrointestinal perforation, iii) post-operative hepatobiliary and/or pancreatic disorders including necrotizing pancreatitis, iv) post-operative intra-abdominal abscess, and v) anastomotic leak.Exclusion criteria a. diagnosis of candidiasis before the enrollment b. exposure in the past 30 days to any antifungal treatment or diagnosis of invasive fungal infection; c. pregnancy or lactation; d. history of allergy to any of the antifungal drugs; e. major immunosuppression conditions including: i. neutropenia (<0.5 \u00d7 109 neutrophils/L [<500 neutrophils/mm3] for >10 days), ii. receipt of an allogeneic stem cell transplant or solid organ transplantation, iii. inherited severe immunodeficiency (such as chronic granulomatous disease or severe combined immunodeficiency), iv. HIV infection with lymphocyte T CD4+ cell count < 200/mmc. f. patients with poor prognosis or unable to sign informed consent.Procedures Pre-randomization proceduresAt the time of patient enrollment (within 24 h from onset of severe sepsis/septic shock), a standardized diagnostic work-up must be performed including at least:i) two sets of blood cultures; ii) 5 surveillance cultures (rectal swab, urine culture, pharyngeal swab, axillary swab, groin swab).iii) in case of re-intervention or percutaneous drainage: Gram stain and culture of intra-abdominal samples; iv) serum BG determination. Antibiotic and antifungal empirical therapy should be started immediately after collection of microbiological samples according with a predefined standard of care (see appendix 1). Once completed this procedures patients will proceed to randomization.Randomization Patient eligible for the study after the beginning of antifungal therapy will be randomized 1:1 to receive (Group A) a BG driven de-escalation strategy or (Group B) a course of antifungal treatment based on the care provider's decision.In both groups, if cultures yield invasive candidiasis (see below) the patient will be managed in according with guidelines and excluded from the per-protocol analysis.In both groups, BG determination will be repeated at day +3, +6 and +10 after starting antifungal therapy.Randomization will be carried out providing closed envelopes to the participating centers immediately before the study onset.", 
    "endDate": "2020-12", 
    "id": "sg:clinicaltrial.NCT03090334", 
    "keywords": [
      "severe sepsis", 
      "septic shock", 
      "abdominal conditions", 
      "antifungal treatment", 
      "invasive candidiasis", 
      "BG determinations", 
      "empirical therapy", 
      "antifungal therapy", 
      "post-operative intra-abdominal abscess", 
      "allogeneic stem cell transplant", 
      "post-operative peritonitis", 
      "recurrent gastrointestinal perforations", 
      "lymphocyte T CD4", 
      "intra-abdominal abscess", 
      "solid organ transplantation", 
      "stem cell transplant", 
      "history of allergy", 
      "standard of care", 
      "invasive fungal infections", 
      "de-escalation strategies", 
      "diagnosis of candidiasis", 
      "randomization patients", 
      "open label", 
      "gastrointestinal perforation", 
      "anastomotic leak", 
      "HIV infection", 
      "percutaneous drainage", 
      "T CD4", 
      "Controlled Trials", 
      "ill patients", 
      "antifungal consumption", 
      "cell transplant", 
      "trial population", 
      "poor prognosis", 
      "immunosuppression conditions", 
      "procedure patients", 
      "patient enrollment", 
      "severe immunodeficiency", 
      "blood cultures", 
      "organ transplantation", 
      "methods study design", 
      "study onset", 
      "surveillance cultures", 
      "pancreatic disorders", 
      "sepsis", 
      "high risk", 
      "patients", 
      "physician's decision", 
      "cell count", 
      "BG values", 
      "candidiasis", 
      "therapy", 
      "colonization status", 
      "fungal infections", 
      "informed consent", 
      "study design", 
      "microbiological samples", 
      "provider decisions", 
      "Gram stain", 
      "infection", 
      "antifungal drugs", 
      "diagnosis", 
      "multicenter", 
      "protocol analysis", 
      "treatment", 
      "negative results", 
      "trials", 
      "days", 
      "primary objective", 
      "consent", 
      "Criterion A.", 
      "broad spectrum", 
      "neutropenia", 
      "peritonitis", 
      "CD4", 
      "abscess", 
      "pancreatitis", 
      "pregnancy", 
      "transplantation", 
      "allergy", 
      "stewardship approach", 
      "prognosis", 
      "group", 
      "septic", 
      "transplant", 
      "immunodeficiency", 
      "perforation", 
      "care", 
      "shock", 
      "drugs", 
      "disorders", 
      "adults", 
      "BG", 
      "enrollment", 
      "risk", 
      "randomization", 
      "onset", 
      "stain", 
      "culture", 
      "exposure", 
      "count", 
      "receipt", 
      "leak", 
      "lactation", 
      "status", 
      "drainage", 
      "guidelines", 
      "B.", 
      "population", 
      "objective", 
      "course", 
      "assessment", 
      "objective I", 
      "samples", 
      "history", 
      "cases", 
      "strategies", 
      "A.", 
      "center", 
      "study", 
      "time", 
      "events", 
      "changes", 
      "decisions", 
      "conditions", 
      "aforementioned events", 
      "MMC", 
      "consumption", 
      "standards", 
      "impact", 
      "analysis", 
      "results", 
      "detailed description", 
      "beginning", 
      "collection", 
      "determination", 
      "labels", 
      "values", 
      "materials", 
      "envelope", 
      "approach", 
      "design", 
      "accuracy", 
      "description", 
      "spectra", 
      "set"
    ], 
    "name": "A B-D-Glucan Driven Antifungal Stewardship Approach to Manage Empirical Therapy in Patients at Very High Risk for Invasive Candidiasis: a Randomized Controlled Trial", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT03090334"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2022-08-04T17:23", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/clinical_trial/clinical_trial_1.jsonl", 
    "startDate": "2017-03", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1007/s00134-013-3109-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007488628", 
          "https://doi.org/10.1007/s00134-013-3109-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00134-014-3404-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027227129", 
          "https://doi.org/10.1007/s00134-014-3404-7"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT03090334"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT03090334'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT03090334'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT03090334'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT03090334'


 

This table displays all metadata directly associated to this object as RDF triples.

174 TRIPLES      15 PREDICATES      163 URIs      155 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT03090334 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:description This is a multicenter, prospective, open-label, randomized trial. Patients with severe abdominal condition developing severe sepsis or septic shock and receiving broad spectrum antibiotic and antifungal treatment will be randomized (1:1) to:discontinue antifungal treatment based on negative (<80 pg/ml) result of 1,3 beta-d-glucan performed on day 0,3,6 and 10continue antifungal treatment according with attending physician's decision. Detailed Description Primary objective:Our objective is to establish whether a strategy based on beta-d-glucan (BG) assessment could achieve reduced antifungal consumption in patients with severe abdominal condition developing severe sepsis and septic shock without any impact on the outcome Secondary objectives i) Assess the accuracy of BG in the diagnosis of invasive candidiasis (IC) in in critically ill patients with a severe abdominal condition who develop severe sepsis or septic shock.ii) Describe the changes over the time of BG value according with colonization status, infection or none the aforementioned events.Material and Methods Study design: a multicenter, open label, randomized trial Population: all the patients with a severe abdominal condition who develop a severe sepsis or septic shock.Inclusion Criteria:adult (≥ 18 year) patients;signed informed consent before surgical procedure;severe sepsis or septic shock;at least one of the following conditions: i) post-operative peritonitis, ii) recurrent gastrointestinal perforation, iii) post-operative hepatobiliary and/or pancreatic disorders including necrotizing pancreatitis, iv) post-operative intra-abdominal abscess, and v) anastomotic leak.Exclusion criteria a. diagnosis of candidiasis before the enrollment b. exposure in the past 30 days to any antifungal treatment or diagnosis of invasive fungal infection; c. pregnancy or lactation; d. history of allergy to any of the antifungal drugs; e. major immunosuppression conditions including: i. neutropenia (<0.5 × 109 neutrophils/L [<500 neutrophils/mm3] for >10 days), ii. receipt of an allogeneic stem cell transplant or solid organ transplantation, iii. inherited severe immunodeficiency (such as chronic granulomatous disease or severe combined immunodeficiency), iv. HIV infection with lymphocyte T CD4+ cell count < 200/mmc. f. patients with poor prognosis or unable to sign informed consent.Procedures Pre-randomization proceduresAt the time of patient enrollment (within 24 h from onset of severe sepsis/septic shock), a standardized diagnostic work-up must be performed including at least:i) two sets of blood cultures; ii) 5 surveillance cultures (rectal swab, urine culture, pharyngeal swab, axillary swab, groin swab).iii) in case of re-intervention or percutaneous drainage: Gram stain and culture of intra-abdominal samples; iv) serum BG determination. Antibiotic and antifungal empirical therapy should be started immediately after collection of microbiological samples according with a predefined standard of care (see appendix 1). Once completed this procedures patients will proceed to randomization.Randomization Patient eligible for the study after the beginning of antifungal therapy will be randomized 1:1 to receive (Group A) a BG driven de-escalation strategy or (Group B) a course of antifungal treatment based on the care provider's decision.In both groups, if cultures yield invasive candidiasis (see below) the patient will be managed in according with guidelines and excluded from the per-protocol analysis.In both groups, BG determination will be repeated at day +3, +6 and +10 after starting antifungal therapy.Randomization will be carried out providing closed envelopes to the participating centers immediately before the study onset.
4 schema:endDate 2020-12
5 schema:keywords A.
6 B.
7 BG
8 BG determinations
9 BG values
10 CD4
11 Controlled Trials
12 Criterion A.
13 Gram stain
14 HIV infection
15 MMC
16 T CD4
17 abdominal conditions
18 abscess
19 accuracy
20 adults
21 aforementioned events
22 allergy
23 allogeneic stem cell transplant
24 analysis
25 anastomotic leak
26 antifungal consumption
27 antifungal drugs
28 antifungal therapy
29 antifungal treatment
30 approach
31 assessment
32 beginning
33 blood cultures
34 broad spectrum
35 candidiasis
36 care
37 cases
38 cell count
39 cell transplant
40 center
41 changes
42 collection
43 colonization status
44 conditions
45 consent
46 consumption
47 count
48 course
49 culture
50 days
51 de-escalation strategies
52 decisions
53 description
54 design
55 detailed description
56 determination
57 diagnosis
58 diagnosis of candidiasis
59 disorders
60 drainage
61 drugs
62 empirical therapy
63 enrollment
64 envelope
65 events
66 exposure
67 fungal infections
68 gastrointestinal perforation
69 group
70 guidelines
71 high risk
72 history
73 history of allergy
74 ill patients
75 immunodeficiency
76 immunosuppression conditions
77 impact
78 infection
79 informed consent
80 intra-abdominal abscess
81 invasive candidiasis
82 invasive fungal infections
83 labels
84 lactation
85 leak
86 lymphocyte T CD4
87 materials
88 methods study design
89 microbiological samples
90 multicenter
91 negative results
92 neutropenia
93 objective
94 objective I
95 onset
96 open label
97 organ transplantation
98 pancreatic disorders
99 pancreatitis
100 patient enrollment
101 patients
102 percutaneous drainage
103 perforation
104 peritonitis
105 physician's decision
106 poor prognosis
107 population
108 post-operative intra-abdominal abscess
109 post-operative peritonitis
110 pregnancy
111 primary objective
112 procedure patients
113 prognosis
114 protocol analysis
115 provider decisions
116 randomization
117 randomization patients
118 receipt
119 recurrent gastrointestinal perforations
120 results
121 risk
122 samples
123 sepsis
124 septic
125 septic shock
126 set
127 severe immunodeficiency
128 severe sepsis
129 shock
130 solid organ transplantation
131 spectra
132 stain
133 standard of care
134 standards
135 status
136 stem cell transplant
137 stewardship approach
138 strategies
139 study
140 study design
141 study onset
142 surveillance cultures
143 therapy
144 time
145 transplant
146 transplantation
147 treatment
148 trial population
149 trials
150 values
151 schema:name A B-D-Glucan Driven Antifungal Stewardship Approach to Manage Empirical Therapy in Patients at Very High Risk for Invasive Candidiasis: a Randomized Controlled Trial
152 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT03090334
153 schema:sdDatePublished 2022-08-04T17:23
154 schema:sdLicense https://scigraph.springernature.com/explorer/license/
155 schema:sdPublisher N108cf859a29849c5b193dde517ff0bb1
156 schema:startDate 2017-03
157 schema:subjectOf sg:pub.10.1007/s00134-013-3109-3
158 sg:pub.10.1007/s00134-014-3404-7
159 schema:url https://clinicaltrials.gov/show/NCT03090334
160 sgo:license sg:explorer/license/
161 sgo:sdDataset clinical_trials
162 rdf:type schema:MedicalStudy
163 N108cf859a29849c5b193dde517ff0bb1 schema:name Springer Nature - SN SciGraph project
164 rdf:type schema:Organization
165 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
166 rdf:type schema:DefinedTerm
167 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
168 rdf:type schema:DefinedTerm
169 sg:pub.10.1007/s00134-013-3109-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007488628
170 https://doi.org/10.1007/s00134-013-3109-3
171 rdf:type schema:CreativeWork
172 sg:pub.10.1007/s00134-014-3404-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027227129
173 https://doi.org/10.1007/s00134-014-3404-7
174 rdf:type schema:CreativeWork
 




Preview window. Press ESC to close (or click here)


...